Says Levinson: "There's nobody that asks, 'can we continue the hot streak' more than myself."
The possible solution:
... Levinson and Desmond-Hellmann are heading out of their comfort zone into a new field: immunology, which focuses on how the body's own defense systems go awry to cause disorders like rheumatoid arthritis, asthma and multiple sclerosis.
Article at Forbes.
Also their next blockbuster may be a clot-buster. (boo! bad joke.)
Motley Fool:
Last week, we asked you to vote in Motley Fool CAPS for the company that you think will be the best drug stock to own in 2007.
Guess who...
More on the stock price:
On Genentech Cramer said that the reason the stock has dropped is because the risks to the model caused a multiple contraction; but now he thinks that will change. Here is why he has a bear case of $104.00 and a bullish case of $140.00And finally it's practically old news by now but here' s a nice post on the licensing supreme court case involving Genentech.
No comments:
Post a Comment